PATHOGENESIS OF AUTOIMMUNE THROMBOCYTOPENIA

自身免疫性血小板减少症的发病机制

基本信息

  • 批准号:
    2751781
  • 负责人:
  • 金额:
    $ 21.9万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1998
  • 资助国家:
    美国
  • 起止时间:
    1998-09-30 至 2003-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (Adapted from applicant's abstract) Idiopathic Thrombocytopenia (ITP) is an autoimmune disorder characterized by production of antiplatelet antibodies and consequent immune-mediated platelet destruction. The initial stimulus for the autoantibody response in ITP is not known, even though it is one of the most common autoimmune diseases affecting both adults and children. ITP may occur as an isolated phenomenon or in association with many conditions, for example: acquired or congenital immune dysregulation, pregnancy, viral infection like HIV or EBV, or systemic lupus erythematosus (SLE). The dominance of antiplatelet autoantibodies in such a wide variety of immune diseases suggests that there may be an alternative mechanisms to antiplatelet production as compared to other autoimmune diseases. In this grant, the applicants present a model for ITP and hypothesize that the platelet itself may act to short circuit the process of antigen specific immunoglobulin production allowing the emergence of autoantibodies which are normally restricted by a network of anti-idiotypic T and B cell clones. Ordinarily, somatic mutation and antigen selection in the B lymphocyte proceed under the strict supervision and symmetrical evolution of idiotype specific T cell clones. In their model, the platelet, mimicking a T cell, could promote polyclonal expansion of previously restricted clones without the concomitant involvement of regulatory T cells or macrophages. To test this hypothesis, the applicants will focus their efforts in following areas: SPECIFIC AIM #1: To determine the effect of ligation of CD40, membrane lg (mig) receptor, and FcRyIII on IL-1alpha and IL-1beta gene expression and production in B cells and dendritic cell/macrophages. SPECIFIC AIM #2: To determine the effect of polyclonal expansion and epitope shifts, they will use limited oligonucleotide substitutions (within the immunoglobin framework or CDR3 region) to measure changes in antigen binding using a uniquely engineered baculovirus protein expression system. Their long term goal is to identify the dysregulation which drives the production of platelet autoantibody. They believe that interruption of this process will return the immune system to a more restricted process of B cell immunoglobulin production allowing T cell regulation to further limit the emergence of autoreactive clones. (End of Abstract)
描述

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Diane J Nugent其他文献

Diane J Nugent的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Diane J Nugent', 18)}}的其他基金

Preventing Bleeding Disorder Complications thru Hemophilia Tx Ctrs in Region IX
通过 IX 区的血友病 Tx Ctr 预防出血性疾病并发症
  • 批准号:
    7233464
  • 财政年份:
    2006
  • 资助金额:
    $ 21.9万
  • 项目类别:
Preventing Bleeding Disorder Complications thru Hemophilia Tx Ctrs in Region IX
通过 IX 区的血友病 Tx Ctr 预防出血性疾病并发症
  • 批准号:
    7895789
  • 财政年份:
    2006
  • 资助金额:
    $ 21.9万
  • 项目类别:
Preventing Bleeding Disorder Complications thru Hemophilia Tx Ctrs in Region IX
通过 IX 区的血友病 Tx Ctr 预防出血性疾病并发症
  • 批准号:
    7279183
  • 财政年份:
    2006
  • 资助金额:
    $ 21.9万
  • 项目类别:
Preventing Bleeding Disorder Complications thru Hemophilia Tx Ctrs in Region IX
通过 IX 区的血友病 Tx Ctr 预防出血性疾病并发症
  • 批准号:
    7679714
  • 财政年份:
    2006
  • 资助金额:
    $ 21.9万
  • 项目类别:
Preventing Bleeding Disorder Complications thru Hemophilia Tx Ctrs in Region IX
通过 IX 区的血友病 Tx Ctr 预防出血性疾病并发症
  • 批准号:
    7487527
  • 财政年份:
    2006
  • 资助金额:
    $ 21.9万
  • 项目类别:
PATHOGENESIS OF AUTOIMMUNE THROMBOCYTOPENIA
自身免疫性血小板减少症的发病机制
  • 批准号:
    6041047
  • 财政年份:
    1998
  • 资助金额:
    $ 21.9万
  • 项目类别:
PATHOGENESIS OF AUTOIMMUNE THROMBOCYTOPENIA
自身免疫性血小板减少症的发病机制
  • 批准号:
    6056571
  • 财政年份:
    1998
  • 资助金额:
    $ 21.9万
  • 项目类别:
PATHOGENESIS OF AUTOIMMUNE THROMBOCYTOPENIA
自身免疫性血小板减少症的发病机制
  • 批准号:
    6184830
  • 财政年份:
    1998
  • 资助金额:
    $ 21.9万
  • 项目类别:
PATHOGENESIS OF AUTOIMMUNE THROMBOCYTOPENIA
自身免疫性血小板减少症的发病机制
  • 批准号:
    6527519
  • 财政年份:
    1998
  • 资助金额:
    $ 21.9万
  • 项目类别:
PATHOGENESIS OF AUTOIMMUNE THROMBOCYTOPENIA
自身免疫性血小板减少症的发病机制
  • 批准号:
    6390187
  • 财政年份:
    1998
  • 资助金额:
    $ 21.9万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了